tetano
Editor, Senior Moderator
J Med Virol
. 2020 May 30.
doi: 10.1002/jmv.26062. Online ahead of print.
COVID-19 Pneumonia Treated With Sarilumab: A Clinical Series of Eight Patients
Maurizio Benucci[SUP] 1 [/SUP], Gianfranco Giannasi[SUP] 2 [/SUP], Paolo Cecchini[SUP] 2 [/SUP], Francesca Li Gobbi[SUP] 1 [/SUP], Arianna Damiani[SUP] 3 [/SUP], Valentina Grossi[SUP] 4 [/SUP], Maria Infantino[SUP] 4 [/SUP], Mariangela Manfredi[SUP] 4 [/SUP]
Affiliations
Abstract
The development of cytokine release syndrome and T cell abnormalities plays a key role in the progression of Coronavirus disease in 2019 (COVID-19). Under these circumstances, persistent viral stimulation leads to a significant increase in circulating cytokines such as interleukin (IL) -6, IL-10 and TNF-α. We describe a clinical series of eight patients treated with Sarilumab an IL-6R inhibitor administered early in Covid-19 pneumonia. This article is protected by copyright. All rights reserved.
Keywords: COVID-19; Interleukin-6; Sarilumab.
. 2020 May 30.
doi: 10.1002/jmv.26062. Online ahead of print.
COVID-19 Pneumonia Treated With Sarilumab: A Clinical Series of Eight Patients
Maurizio Benucci[SUP] 1 [/SUP], Gianfranco Giannasi[SUP] 2 [/SUP], Paolo Cecchini[SUP] 2 [/SUP], Francesca Li Gobbi[SUP] 1 [/SUP], Arianna Damiani[SUP] 3 [/SUP], Valentina Grossi[SUP] 4 [/SUP], Maria Infantino[SUP] 4 [/SUP], Mariangela Manfredi[SUP] 4 [/SUP]
Affiliations
- PMID: 32472703
- DOI: 10.1002/jmv.26062
Abstract
The development of cytokine release syndrome and T cell abnormalities plays a key role in the progression of Coronavirus disease in 2019 (COVID-19). Under these circumstances, persistent viral stimulation leads to a significant increase in circulating cytokines such as interleukin (IL) -6, IL-10 and TNF-α. We describe a clinical series of eight patients treated with Sarilumab an IL-6R inhibitor administered early in Covid-19 pneumonia. This article is protected by copyright. All rights reserved.
Keywords: COVID-19; Interleukin-6; Sarilumab.